Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21572806 | 0.87 | GAA (0.41) | GAATSHRABCC4LMNAPTGS1 | |
| SCHEMBL20583638 | 0.87 | GAA (0.43) | GAATSHRABCC4LMNAPTGS1 | |
| SCHEMBL20583639 | 0.87 | GAA (0.43) | GAATSHRABCC4LMNAPTGS1 | |
| SCHEMBL21572795 | 0.85 | GAA (0.49) | GAATSHRABCC4LMNAPTGS1 | |
| SCHEMBL21572788 | 0.83 | TSHR (0.47) | GAATSHRABCC4LMNAPTGS1 | |
| SCHEMBL21572794 | 0.82 | GAA (0.46) | GAATSHRABCC4LMNAPTGS1 | |
| SCHEMBL21572810 | 0.81 | GAA (0.45) | GAATSHRABCC4LMNAPTGS1 | |
| SCHEMBL21572801 | 0.81 | LMNA (0.45) | GAATSHRABCC4LMNAPTGS1 | |
| SCHEMBL21572797 | 0.80 | LMNA (0.53) | GAATSHRABCC4LMNAPTGS1 | |
| SCHEMBL20583245 | 0.79 | GAA (0.43) | GAATSHRABCC4LMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370739-B2 | Sacubitril intermediate and preparation method thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-06-28 | — | — | US | disclosed |
| US-10479753-B2 | Sacubitril intermediate and preparation method thereof | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2019-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370739-B2 | Sacubitril intermediate and preparation method thereof | DPP4, ACE, DPP8 | GAA 63/4885TSHR 3965/4885ABCC4 3539/4885 |
| US-10479753-B2 | Sacubitril intermediate and preparation method thereof | ACE, DPP4, SI | GAA 63/4885TSHR 3906/4885ABCC4 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.